Surrozen (SRZN) Receivables - Net (2022 - 2026)
Surrozen (SRZN) recorded quarterly Receivables - Net of $5.0 million in Q1 2026, up 115.8% quarter-over-quarter from $2.3 million in Q3 2025, and up 134.74% on a YoY basis from $2.1 million in Q1 2025.
Surrozen (SRZN) Receivables - Net (2022 - 2026) Analysis & Trends
Surrozen's Receivables - Net history runs 5 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Receivables - Net rose 134.74% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (up 134.74% YoY), while the FY2024 annual figure was $2.0 million, down 5.25% from the prior year.
- Receivables - Net was $5.0 million for Q1 2026 at Surrozen, up from $2.3 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $12.2 million in Q3 2024 to a low of $2.0 million in Q4 2022.
- Historically, Receivables - Net has averaged $3.1 million across 5 years, with a median of $2.1 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net surged 516.58% in 2024, then sank 81.0% in 2025.
- A 5-year view of Receivables - Net shows it stood at $2.0 million in 2022, then advanced by 8.8% to $2.2 million in 2023, then slipped by 5.25% to $2.0 million in 2024, then gained by 13.63% to $2.3 million in 2025, then soared by 115.8% to $5.0 million in 2026.
- The last three Receivables - Net figures came in at $5.0 million (Q1 2026), $2.3 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.00 Mn |
| Mar 31, 2026 | 5.00 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 12.20 Mn |
| Sep 30, 2024 | 12.20 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Sep 30, 2023 | 1.98 Mn |